Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights
U.S. neurologists increasingly favor Novartis’ MS portfolio, particularly Kesimpta Exton, PA., February 17, 2023 – According to Biogen’s earnings call